Elie Dib, MD
Medical Oncology · Ypsilanti, MINPI 1174576219
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $224 of the $252 with a category attached, or 88.5%. Abbott accounts for 66.4% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $185, 3.3 times the $56 reported in 2019. That places this record below the midpoint for medical oncology clinicians in MI, where the typical reported total is $1,832.
Across 5 payments — averaging $50.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$168
- Foundation Medicine, Inc.$56
- Regeneron Healthcare Solutions, Inc.$17
- Gilead$12
Across 21 payments — averaging $11,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$213K
- AbbVie$17K
- Genentech, Inc.$6K
- Pfizer$4K
- Merck$450
What the payments were for
- Food & beverage$22489%
- Education$2911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $168 |
| Foundation Medicine, Inc. | 1 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Gilead | 1 | $12 |
How this compares
$252 in reported general payments places this provider in the 30th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 61 | $731,897 |
| FotivdaTivozanib Hcl | 24 | $682,393 |
| RevlimidLenalidomide | 31 | $522,455 |
| TagrissoOsimertinib Mesylate | 28 | $440,817 |
| CalquenceAcalabrutinib Maleate | 29 | $407,341 |
| NubeqaDarolutamide | 29 | $384,810 |
| PomalystPomalidomide | 13 | $306,271 |
| ErleadaApalutamide | 21 | $303,003 |
| StivargaRegorafenib | 11 | $243,152 |
| JakafiRuxolitinib Phosphate | 12 | $211,918 |
| BrukinsaZanubrutinib | 13 | $194,474 |
| IbrancePalbociclib | 12 | $185,186 |
| ImbruvicaIbrutinib | 12 | $182,929 |
| XtandiEnzalutamide | 16 | $148,654 |
| Abiraterone Acetate | 82 | $111,543 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ypsilanti
- Tareq Al BaghdadiYpsilanti$116K
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Sami BrakeGrand Rapids$251K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
- Charles SchifferDetroit$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.